Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration

Janusz Blasiak, 1 Russel J. Reiter, 2 and Kai Kaarniranta 3,4

1 Department of Molecular Genetics, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
2 Department of Cellular & Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA
3 Department of Ophthalmology, University of Eastern Finland, 70211 Kuopio, Finland
4 Department of Ophthalmology, Kuopio University Hospital, 70029 Kuopio, Finland

Correspondence should be addressed to Janusz Blasiak; jblasiak@biol.uni.lodz.pl

Received 8 June 2016; Accepted 9 August 2016

Academic Editor: Joanna Lecka

Copyright © 2016 Janusz Blasiak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Melatonin, an indoleamine, is synthesized mainly in the pineal gland in a circadian fashion, but it is produced in many other organs, including the retina, which seems to be especially important as the eye is a primary recipient of circadian signals. Melatonin displays strong antioxidative properties, which predispose it to play a protective role in many human pathologies associated with oxidative stress, including premature aging and degenerative disease. Therefore, melatonin may play a role in age-related macular degeneration (AMD), a disease affecting photoreceptors, and retinal pigment epithelium (RPE) with an established role of oxidative stress in its pathogenesis. Several studies have shown that melatonin could exert the protective effect against damage to RPE cells evoked by reactive oxygen species (ROS), but it has also been reported to increase ROS-induced damage to photoreceptors and RPE. Melatonin behaves like synthetic mitochondria-targeted antioxidants, which concentrate in mitochondria at relatively high levels; thus, melatonin may prevent mitochondrial damage in AMD. The retina contains telomerase, an enzyme implicated in maintaining the length of telomeres, and oxidative stress inhibits telomere synthesis, while melatonin overcomes this effect. These features support considering melatonin as a preventive and therapeutic agent in the treatment of AMD.

1. Introduction

Melatonin, N-acetyl-5-methoxytryptamine, indole found in virtually all forms of life, from bacteria to humans, is a highly potent biomolecule with many functions in biological systems, the vast majority of which are beneficial [1–5]. Moreover, melatonin has a high safety profile [6]. Melatonin functions are either receptor-dependent or receptor-independent [7]. The former include circadian rhythm control and sleep regulation, whereas the latter include the detoxification of reactive oxygen species (ROS) and other reactive molecules. Due to this latter function, melatonin plays a role in cellular defense against oxidative stress [8–10].

Melatonin is released from the pineal gland in a circadian fashion, which is controlled by suprachiasmatic nuclei (SCN) [11]. However, many other tissues and organs include the retina, lens, gastrointestinal tract, and skin synthesize melatonin [12, 13]. Melatonin’s antioxidant properties combined with its circadian regulatory properties may be especially important in ophthalmology as the eye is a primary receptor of rhythmic light/dark signals sent from retinal ganglion cells to SCN; also the retina is a region of intense blood flow resulting in high oxygen levels in this organ. A single-pulse light stimulation resulted in an over 50% increase in the retinal blood flow [14, 15]. These high concentrations of oxygen require a strict redox control to prevent oxidative stress. Also light that reaches the retina generates ROS that contribute to oxidative stress [16, 17]. Moreover, retinal cells and retinal pigment epithelium (RPE) cells are rich in mitochondria, which are a major source of ROS produced by the electron transport chain (ETC) [18].

Age-related macular degeneration (AMD) is an eye disease characterized by degenerative changes in the central retina known as the macula [19] (Figure 1(a)). It is a complex disease, whose pathogenesis results from the interaction between many genetic and environmental factors. The most
Figure 1: (a) Photograph of the fundus of the central retina. Yellow arrow indicates fovea in central macula and black arrow identifies the optic nerve head. (b) Optical coherent tomography image from a normal retina. GCL, ganglion cells; PR, photoreceptors; RPE, retinal pigment epithelium.

Figure 2: Major AMD environmental risk factors. The thickness of arrows corresponds to a putative significance of a particular factor. These factors are associated with increased ROS production which contributes to oxidative stress. ROS, reactive oxygen species.

important genetic factor in AMD pathogenesis seems to be variations in the complement factor H (CFH).

Major environmental risk factors for AMD are age, smoking, oxidative stress, high-fat diet, light, and UV (Figure 2) [20]; all of these increase production of highly reactive and toxic ROS. Thus, oxidative stress is a consequence of all the main environmental risk factors. Moreover, the influence of variations in the CHF can be modulated by oxidative stress. Female gender, Caucasian origin, and light iris are frequently mentioned as minor AMD risk factors.

The nature of the interaction between genetic and environmental factors is mostly unknown, but oxidative stress is unequivocally associated with the induction and development of AMD. The fundamental question as whether oxidative stress is a casual factor for AMD or merely accompanies disease progression remains unanswered, however. This problem is additionally complicated by the age-dependent accumulation of lipofuscin in highly pigmented postmitotic RPE cells. The RPE-derived pigment protects the neuroretina from the excess of light exposure [21]. Normal and young RPE cells effectively degrade proteins in lysosomes, but this process is estimated to be impaired in aging cells which ultimately lead to the detrimental accumulation of lipofuscin in lysosomes [22]. Lipofuscin can be photoxidized yielding ROS. Therefore, the retina is prone to oxidative stress and its important functions of receiving light signals, contributing to circadian regulation, and releasing melatonin in a circadian fashion are negatively impacted in AMD. The implication is that melatonin likely plays a role in AMD pathogenesis. In this review we summarize some aspects of mutual relationships between melatonin and retinal physiology/pathology to document some potential preventive and therapeutic potential of melatonin in AMD.

2. The Retina as a Light-Sensitive Ocular Clock

The retina is an essential part of the back of the eye; it consists of layers of cells about 0.5 mm in thickness (Figure 1). It includes ganglion cells, located innermost, and the photosensors (photoreceptors), the rods and cones, lying closest to the RPE (Figure 1(b)). The human retina contains three layers of nerve cells and two regions of synapses. Three types of glial cells are found in the human retina: Muller cells, astroglia, and microglia. Macula (macula lutea) is a yellowish area located near the center of the retina, which is responsible for the central vision and the visual acuity (Figure 1). It has a specific structure in its center, called the fovea, which contains exclusively cones, specialized nerve cells associated with color vision and perception of tiny objects.

As the nervous system exhibits circadian rhythm and since the retina is considered as a part of the brain and is influenced by the day/night cycle, it is not surprising that it
has its own retinal clock. In general, there are several genes, collectively known as “clock genes,” the expression of which is necessary for circadian rhythmicity [23]. The products of these genes regulate transcription of “clock controlled” genes. More precisely, the molecular clock in the retina is controlled by two feedback-loops: one is positive and consists of the transcription factors BMAL1 and CLOCK, activating in a heterodimeric form transcription of the PERIOD and CRYPTOCHROME genes. The second is a negative loop where cytoplasmic PERIOD and CRYPTOCHROME form a heterodimer, which enters the nucleus and inhibits transcription of the promoters of their own genes. The retinal circadian rhythm is independent of the rest of the nervous system as it was demonstrated by the release of melatonin in a circadian fashion by isolated retinal cells [24]. The expression of the CLOCK gene was reported not to be needed for molecular rhythms in the mouse SCN [25]. The mouse retina differs from its bird and amphibian counterparts, where the photoreceptors are internal circadian oscillators involved in rhythmic release of melatonin [26–28].

At least some of the clock controlled genes have circadian E boxes in their promoters. The nucleotide sequence of the E box contains the core motif 5'-CACGTG clock, bound periodically by the CLOCK/BMAL1 heterodimer [29]. It is not the only interaction important for the circadian regulation in the retina as several posttranslational modifications, including acetylation, phosphorylation, sumoylation, and ubiquitination, were shown to have roles in this phenomenon as well [30, 31]. Sustained circadian rhythms in the retina were demonstrated in Müller glia cells which express canonical circadian clock genes [32].

The retinal circadian clock influences many processes occurring in the retina, including melatonin secretion, dopamine synthesis, visual sensitivity, extracellular pH, and intraocular pressure as well as some electroretinogramic responses [33]. The clock is also involved in some pathological processes in the retina including degeneration of photoreceptors upon interaction with light [34, 35]. In spite of its influential effects on the function of the retina in mammals, the organization and origin of the retinal clock are not completely known.

3. Melatonin in the Eye

Although melatonin was first identified as being synthesized in the pineal gland, it is also produced in many other organs [12, 13], where it is believed to have important local functions as paracoid or autacoid [36]. In the retina, melatonin is released mainly by photoreceptor cells but can be also produced by some other cells in pathological conditions [37]. It was shown that the rat retina continued producing melatonin in a circadian manner even after pinealectomy [3]. Thus, retinal melatonin production is under the control of retinal circadian clock, resulting in its high concentration in the night and low level during the day, although its amount is small compared to its pineal counterpart [38, 39].

As in the pineal gland, nocturnal melatonin synthesis in the retinal photoreceptors of mammals has as its precursor the amino acid tryptophan [40, 41]. The enzyme aryalkylamine N-transferase (AANAT) is locally controlled since its transcription in the photoreceptors is regulated by a circadian clock that is independent of the hypothalamus [37, 42–44]. The AANAT encoding gene, the AANAT gene, contains circadian E box enhancers and AMP-response elements in its promoter, contributing to its circadian expression [45, 46]. It was shown in that studies that the chicken retina contained a TTATT repeat sequence and an analog of the canonical CRE (c-AMP-response element) to drive AANAT expression from its basal and c-AMP-driven promoters and these sequences are targeted by CREB, c-FOS, and Jun-D transcription factors. Also posttranslational regulation of the AANAT gene is subjected to circadian control [42, 43]. Acute light exposure, mediated by dopamine, induces a reduction in the c-AMP level in photoreceptors, which decreases binding of cyclic AMP-response elements in the AANAT promoter and stimulates dephosphorylation of AANAT and its degradation [47, 48]. Another enzyme essential for melatonin biosynthesis in the retina is tryptophan hydroxylase, converting tryptophan to 5-hydroxytryptophan (5HTP), and is encoded by the Tph gene, the expression of which in the retina is controlled in a circadian manner, exhibiting a similar daily rhythm to AANAT activity [49, 50].

It is not definitely proven whether the intact human retina produces its own melatonin or takes it up from the blood [51]. The melatonin–synthesis system is, however, functional in cultures of human retinal pigment epithelium cell, ARPE-19 [52]. Although melatonin receptors, MT1 and MT2, are present in the human retina, the presence of acetylseryotonin methyltransferase (ASMT) is very low, so the receptors can bind circulating melatonin [53, 54]. However, ASMT and AANAT were detected in the retina of Macaca mulatta, but the transcript concentration of the former is very low and detected only at night [53]. In these studies mRNA levels of AANAT were constant for the entire twenty-four hours, but its activity increased at night. This suggests that melatonin in the human retina is produced not associated with the increased expression of genes involved in its biosynthesis but rather by the activation of their protein products; this suggestion is supported by the studies in human retinoblastoma cells [55]. Retinal melatonin receptors in humans are located in the rod photoreceptors and ganglion cells [54]. Melatonin influences the electroretinogram response suggesting that it can play a role in the shifting between day- and night-activity in the retina and it does so by regulating the retina clock [56–58].

Melatonin modulates the expression of retinal genes, that is, PER1, PER2, and BMAL1, responsible for controlling circadian rhythms in this tissue, as well as the genes regulating their expression: DBP, NAMPT, and c-FOS were rhythmically modulated in the mouse retina and in the photoreceptor layer [59]. However, inhibition of melatonin signaling essentially changed the pattern of expression of these genes, but only in ganglion cells, while in the photoreceptor layer only BMAL1 expression pattern is altered. Thus, melatonin is important in the regulation of the expression of clock genes especially in the ganglion cells layer and less so in the photoreceptors. These results may seem somewhat surprising as melatonin
Figure 3: Protein aggregation in aged RPE cells is involved in AMD pathology. RPE cells are constantly exposed to oxidative stress. In daily visual cycle photoreceptor outer segments are phagocytosed by the RPE; this process is referred to as heterophagy. The cellular elements are degraded in the lysosomes. In aged RPE cells, lipofuscin accumulates in lysosomes as a result of a coincident decline of lysosomal enzyme activity and autophagy flux. Lipofuscin is an autooxidant that increases damage induced by oxidative stress in mitochondrial and nuclear DNA. Disturbed clearance and accumulated toxic compounds in RPE trigger the inflammation and explain the AMD-associated biogenesis of extracellular drusen formation. Melatonin both inhibits oxidative damage and suppresses inflammation.

Figure 4: Fundus autofluorescence (FAF) from a dry AMD case. Arrow indicates the edge of lipofuscin accumulation and damage of RPE cells.
the stress can be targeted in AMD prevention and therapy. The AREDS (Age-Related Eye Disease Study) found that supplementation of the diet by antioxidants and zinc (the AREDS formulation) could reduce the risk of developing advanced AMD by 25%, although this result was subsequently questioned [71]. Our recent observation shows that nutraceuticals with omega-fatty acids and resveratrol induce lysosomal autophagy and protect RPE cells [72].

As DNA repair is a major pathway of cellular defense against oxidative stress, we studied the role of oxidative DNA damage and repair in the pathogenesis of AMD. This type of DNA damage can have various forms, but the most frequent ones are oxidative modifications to the DNA bases [73]. They are removed by base excision repair (BER) pathway, in which DNA glycosylases play a pivotal role [74]. These enzymes cut the N-glycosyllic bond between sugar and the oxidatively modified base, leaving an apurinic or apyrimidinic (AP) site, which is then converted by an AP endonuclease into DNA single-strand termini are then processed to produce 3'-OH and 5'-P ends, which can be a substrate for a DNA polymerase, assisted by auxiliary proteins. Finally, lacking phosphodiester bond is sealed by a DNA ligase. Thus, several enzymes and nonenzymatic proteins are crucial for removing oxidative DNA damage and their abnormal expression can be important in pathogenesis of many human diseases [75]. Such disturbed expression can be determined by variation in the sequence of genes encoding BER proteins. We studied several polymorphism types in the BER genes in AMD patients obtaining some correlations, which support the hypothesis related to the involvement of oxidative DNA damage and repair in AMD pathogenesis [76].

As mentioned previously, the most important genetic AMD risk factors are mutations in the genes encoding the complement factor H, with the rs1061170T>C variant identified by genomewide association studies [77]. Therefore, as oxidative stress is a major environmental risk factor, it is reasonable to investigate the role of the interaction between these two influences in AMD pathogenesis. It was suggested that chronic oxidative stress may initiate pathological changes in the retina due to damage to retinal biomolecules, resulting in chronic inflammation with the involvement of the complement system, with the pronounced role of CFH and eventually invasive immune cells contributing to retinal changes typical for AMD [66, 78] (Figure 4).

As already noted, the retina has its own circadian system, which can be important for both its physiology and pathology, implicating a potential role of melatonin in retinal physiological and pathological phenomena. The role of circadian rhythms in oxidative stress-related pathogenesis of AMD was recently reviewed by Fanjul-Moles and Lopez-Riquelme [79].

5. Melatonin as an Antioxidant in the Retina

Melatonin exerts its antioxidant actions by several mechanisms, including direct ROS scavenging, stimulating antioxidant enzymes, improving the functioning of mitochondrial ETC, reducing the extent of electron leakage from the mitochondrial complexes, and improving the efficacy of other antioxidants [4, 80]. The antioxidant action of melatonin can be also expressed by increasing the efficacy of removing oxidative DNA damage [81].

Melatonin exerts protective effects in several experimental models of oxidative stress-related diseases of the human eye; these are summarized in an old review by Siu et al. [82]. The diseases include photokeratitis, cataract, glaucoma, retinopathy of prematurity, and ischemia/reperfusion injury. The studies reviewed herein suggest the potential use of melatonin as a prophylaxis to protect against disturbance of visual functions, especially in the elderly. Moreover, the results justify continued research related to the molecular mechanisms of action of melatonin in the eye.

A one-minute exposure to light produced ROS in isolated and dark adapted frog photoreceptors; this process was inhibited by picomolar concentrations of melatonin, which, on the other hand, increased the prooxidant effect of the light at higher concentrations [83]. In a similar study melatonin was shown to act synergistically with vitamin E to reduce the level of nitric oxide-induced lipid peroxidation in the retina of rats [84]. Melatonin protects against lipid peroxidation induced in PUFAs in rod outer membrane segment cells [85].

Melatonin at concentration ranging from 10^{-10} to 10^{-4} protects human retinal epithelium cells in culture against cytotoxic effects of hydrogen peroxide [86]. Luzindole, a melatonin membrane-receptor antagonist, exhibited a differential modulation of the protective effect of melatonin on RPE cells, which depended on melatonin concentration. At a low, up to 10^{-8} M, concentration range, luzindole completely blocked this effect, but at concentrations above 10^{-6} M the receptor antagonist did not affect melatonin action. Therefore, it can be concluded from that study that melatonin can exert the protective effects against hydrogen peroxide-induced damage in human RPE either indirectly by the activation of melatonin receptors or directly via its antioxidant effect or by a combination of both, depending on its concentration. However, high exogenous concentrations of melatonin increase light-induced damage to photoreceptor [35].

Oxidation of xanthine or hypoxanthine is catalyzed by xanthine oxidase (XO) and produces superoxide radical and hydrogen peroxide, which can yield hydroxyl radicals [87]. XO was detected in the endothelium of retinal capillaries and some cone photoreceptors [88]. It was shown that melatonin protected cultured human retinal neurons from the detrimental action of ROS-producing XO, which also prevents the associated apoptosis and necrosis [89]. Melatonin was also shown to be effective against lipid peroxidation, assessed by the content of malondialdehyde in rat retinal homogenates [90].

Hydrogen peroxide can induce a short-term oxidative stress, which leads to oxidative DNA damage. As mitochondria are a generous source of ROS, mitochondrial DNA (mtDNA) is a prime candidate to ROS-induced damage. Melatonin was shown to be effective in the protection...
of mtDNA of ARPE-19 cells against hydrogen peroxide-induced damage [91]. In that study, melatonin did not exhibit a protective effect against cytotoxicity induced by \( \text{H}_2\text{O}_2 \). Another major source of free radical production is ischemia/reperfusion. In a single study, melatonin was found not to protect the retina from ischemia/reperfusion injury [92].

Glucoma, a major cause of loss of vision worldwide, is mostly characterized by increased intraocular pressure (IOP). IOP underlies the degeneration of retinal ganglion cells and damage to optic nerve head; oxidative stress may be important for its pathology [93, 94]. A significant decrease in retinal antioxidant defense was observed in a rat model mimicking human open-angle glaucoma and since melatonin ameliorated this process, the indoleamine may be a useful component of a therapeutic strategy in glaucoma [95]. This is also justified by a hypotensive effect of melatonin resulting in a reduction of IOP in a mouse glaucoma model [96].

Retinopathy is a major complication of type 2 diabetes mellitus and oxidative stress is considered as an important pathogenic factor in this disease [97]. The retina of streptozotocin-induced diabetic rat was reported to have depleted glutathione and downregulation of the enzyme critical for its production, glutamate cysteine ligase [98]. Melatonin upregulated the enzyme by the maintaining of critical for its production, glutamate cysteine ligase [98]. Melatonin upregulated the enzyme by the maintaining of cytochrome P450 and cytochrome P450 genes and exerted no effect of the Nrf2-regulated genes in the retina of these rats [107].

It has been hypothesized that AMD is initiated by aged and damaged RPE cells [108] (Figure 3). It also was shown that the process of telomere shortening, critical for senescence, could be dependent on environmental oxidative stress and the activity of antioxidant enzymes [109]. Therefore, it is justified to examine the possible effects of melatonin on the senescence of RPE cells in AMD patients. Moreover, it was hypothesized that melatonin can stimulate the activity of telomerase to rebuild the telomeres in senescent RPE cells in AMD retinas, which are important for both prevention and therapy of AMD [110]. The retina contains potentially active telomerase, which can be implicated in functions other than telomere maintenance functions, including expression of retinal cell phenotypes [111]. Overexpression of the catalytic subunit of the enzyme was observed in a mouse model of retinopathy [112]. A high expression of telomerase observed in retinoblastoma is not surprising as it is considered as a major mechanism of cancer cell immortality [113, 114]. Melatonin modulates the expression and activity of telomerase [3].

Retinal hypoxia in AMD results in the breakdown of the inner retina-blood-barrier while melatonin protects against this change [115, 116]. The mechanism of this effect can include the interaction of melatonin with vascular endothelial growth factor (VEGF), as melatonin was reported to decrease the level of VEGF in hypoxia in the choroidal plexus, which may be crucial in preventing the development of exudative form of AMD [117]. As anti-VEGF strategy is routinely used in the therapy of exudative AMD, it can be anticipated whether melatonin supplementation might decrease the number of intravitreal injections [118, 119].
Blue light is used to send information to synchronize internal biological rhythm with changes in the environment and melatonin is involved in this process [120]. However, these wavelengths are also an AMD pathogenesis factor [16]. This justifies the randomized controlled trial, called the CLOCK-IOL color study, on the effect of intraocular lenses blocking blue light on circadian rhythmicity which has been set [121]. However, it should be taken into account that both the involvement of environmental exposure to light in AMD pathogenesis and the protective role of blue-blocking intraocular lenses in AMD have been questioned [122].

Impaired autophagy has been associated with AMD which is consistent with the accumulation of lipofuscin and extracellular drusen [123, 124] (Figure 3). Interestingly, melatonin was shown to influence autophagy in several studies [125, 126]. Therefore, melatonin reduces deregulated autophagy in AMD and inhibits progression of the disease.

It is intriguing that AMD affects only a small part of the retina, that is, the macula. The macula comprises only 2.1% of the retina; when it undergoes degeneration the remainder of the retina remains unaffected. The reason for this is not completely clear, but several potential explanations can be considered. The central retina, including the macula, is substantially thicker than peripheral retina, which is especially seen in the relative thickness of ganglion cell layers, inner plexiform layers, and nerve fiber layer; the increased thickness is due to larger number and higher packaging density of ganglion cells in the central compared to the peripheral retina. As a consequence, cells in the central retina may be more susceptible to chemical or physical factors important for AMD pathogenesis. As mentioned above, the retina is characterized by an intense blood supply, but this feature also differs in the central and peripheral retina. The blood supply to the avascular macula depends exclusively on the choroidal circulation, while the vascularized peripheral retina relies on both the central retinal and choroidal blood vessels. Therefore, degeneration of RPE cells may be more severe for the central retina cells, whilst the peripheral retina cells can survive the consequences of RPE degeneration as its blood supply is more abundant. Moreover, melatonin receptors are located on the rod photoreceptors, which are mainly in the periphery; this could be a factor in determining the location of AMD. Finally, if we assume that melatonin acts in the retina as an antioxidant, its uptake from the retinal blood vessels in the periphery may be more efficient than in the macula. This difference could be, at least in part, responsible for higher susceptibility of the central retina to oxidative stress following RPE damage. In reference to degenerative conditions of the retina, the location of retinitis pigmentosa (RP), an eye disease affecting predominantly the peripheral retina, thus topographically different from AMD, is intriguing. The issue of the significance of melatonin in RP clearly has not been adequately addressed.

7. Conclusion and Perspectives

It is important to have a further insight into differential involvement of melatonin in regulation of circadian genes in photoreceptors and ganglion cells. This can lead to the identification of cells in the inner and ganglion layers affected by melatonin signaling.

As we mentioned in the Introduction, retinal cells, including RPE cells, are rich in mitochondria and these organelles are a major source of ROS, which are natural products of the functioning of the mitochondrial ETC. These ROS play a significant role in AMD pathogenesis. However, chronic oxidative stress in RPE cells can influence the dynamics of the mitochondrial network, that is, the ratio of mitochondrial association (fusion) and disassociation (fission) [127, 128]. Consequently, mitochondria are both a source and a target of ROS in RPE cells and are likely involved in AMD pathogenesis; this is supported by the results of a large variety of publications [129–131]. Postmortem studies of eyes affected by AMD revealed excess damage to mitochondrial DNA, which is a result of oxidative stress [132, 133]. Therefore, melatonin involvement in the mitochondrial control could be addressed in AMD. The association between melatonin and mitochondria is supported by the prediction that mitochondria may be primary sites for melatonin synthesis [134]. Moreover, melatonin was shown to behave as a synthetic, mitochondria-targeted antioxidant; it is reported to be in high concentrations in this organelle [80].

The activity of telomerase in the retina is especially intriguing, as this enzyme is usually activated in cancer cells [135]. The involvement of telomerase in the maintenance of telomere length in retinal cells and influence of oxidative stress and melatonin in this process deserve further attention as telomere shortening is associated not only with normal aging, but also with premature aging and age-related diseases [136, 137]. It should be tempting to develop this topic relative to AMD therapy. The usefulness of cell and gene therapy targeted to telomerase was evaluated [138]; it seems that melatonin targeting this enzyme in the retina could be a direct strategy to prevent AMD. The role of telomerase in oxidative stress associated with AMD is supported by the observation that the activity of this enzyme in human retinal progenitor cells was sensitive to oxygen concentration [139]. It was also observed that ectopic expression of telomerase extended the life span of human retinal microvascular cell line [140].

The antioxidant effect of melatonin, which would likely be crucial for its protective role in AMD, can be broadly divided into receptor-dependent and receptor-independent processes. Although the latter can be attributed to radical-scavenging properties of melatonin, the former needs further research. The role of melatonin in the pathogenesis of ocular diseases is supported by the basic fact that the concentration of this indole in ocular aqueous humors (10^{-9}–10^{-8}) can be higher than in the serum (2 × 10^{-10}–10^{-7}) [141, 142].

There are too few clinical trials with melatonin in AMD patients to establish a reliable relationship between the level of this indole and AMD occurrence/progression, but some data suggest a reduced level of melatonin in AMD [86, 104]. Since melatonin generally lacks significant toxicity, a clinical study with melatonin supplementation for AMD prevention and treatment should be considered. Experience coming from other clinical trials with melatonin suggests that daily
supplementation with melatonin could be sufficient to check clinical effectiveness of melatonin in AMD [86].

Competing Interests
The authors declare that there are no competing interests regarding the publication of this paper.

Acknowledgments
This study was supported by the Academy of Finland (296840), the Finnish Eye Foundation, and the Kuopio University Hospital VTR Grant (5503743).

References
[1] T. C. Erren and R. J. Reiter, "Melatonin: a universal time messenger," Neuroendocrinology Letters, vol. 36, no. 3, pp. 187–192, 2015.
[2] E. Peschke, I. Bähr, and E. Mühlbauer, "Experimental and clinical aspects of melatonin and clock genes in diabetes," Journal of Pineal Research, vol. 59, no. 1, pp. 1–23, 2015.
[3] R. J. Reiter, D. X. Tan, and A. Galano, "Melatonin: exceeding expectations," Physiology, vol. 29, no. 5, pp. 325–333, 2014.
[4] D.-X. Tan, L. C. Manchester, E. Esteban-Zubero, Z. Zhou, and R. J. Reiter, "Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism," Molecules, vol. 20, no. 10, pp. 18886–18906, 2015.
[5] Z. Xin, S. Jiang, P. Jiang et al., "Melatonin as a treatment for gastrointestinal cancer: a review," Journal of Pineal Research, vol. 58, no. 4, pp. 375–387, 2015.
[6] L. P. Andersen, I. Gogenur, J. Rosenberg, and R. J. Reiter, "The safety of melatonin in humans," Clinical Drug Investigation, vol. 36, no. 3, pp. 169–175, 2016.
[7] R. J. Reiter, D. X. Tan, L. C. Manchester, M. Pilar Terron, L. J. Flores, and S. Koppisepi, "Medical implications of melatonin: receptor-mediated and receptor-independent actions," Advances in Medical Sciences, vol. 52, pp. 11–28, 2007.
[8] S. Liu, Y. Guo, Q. Yuan et al., "Melatonin prevents neural tube defects in the offspring of diabetic pregnancy," Journal of Pineal Research, vol. 59, no. 4, pp. 508–517, 2015.
[9] B. Poggegger, R. J. Reiter, D.-X. Tan, L.-D. Chen, and L. C. Manchester, "Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis," Journal of Pineal Research, vol. 14, no. 4, pp. 151–168, 1993.
[10] F. Torres, A. González-Candia, C. Montt et al., "Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep," Journal of Pineal Research, vol. 58, no. 3, pp. 362–373, 2015.
[11] J. H. Stehle, A. Saade, O. Rawashdeh et al., "A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases," Journal of Pineal Research, vol. 51, no. 1, pp. 17–43, 2011.
[12] D. Acuña-Castroviejo, G. Escames, C. Venegas et al., "Extraneuronal melatonin: sources, regulation, and potential functions," Cellular and Molecular Life Sciences, vol. 71, no. 16, pp. 2997–3025, 2014.
[13] R. J. Reiter, S. A. Rosales-Corral, L. C. Manchester, X. Liu, and D.-X. Tan, "Melatonin in the biliary tract and liver: health implications," Current Pharmaceutical Design, vol. 20, no. 30, pp. 4788–4801, 2014.
[14] G. Garhöfer, K. H. Huemer, C. Zawinka, L. Schmetterer, and G. T. Dorner, "Influence of diffuse luminance flicker on choroidal and optic nerve head blood flow," Current Eye Research, vol. 24, no. 2, pp. 109–113, 2002.
[15] G. Michelson, A. Patzelt, and J. Harazny, "Flickering light increases retinal blood flow," Retina, vol. 22, no. 3, pp. 336–343, 2002.
[16] T. H. Margrain, M. Boulton, J. Marshall, and D. H. Sloney, "Do blue light filters confer protection against age-related macular degeneration?" Progress in Retinal and Eye Research, vol. 23, no. 5, pp. 523–531, 2004.
[17] A. Yoshida, Y. Shiotsu-Ogura, S. Wada-Takahashi, S.-S. Takahashi, T. Toyama, and F. Yoshino, "Blue light irradiation-induced oxidative stress in vivo via ROS generation in rat gingival tissue," Journal of Photochemistry and Photobiology B: Biology, vol. 151, pp. 48–53, 2015.
[18] A. Terman, T. Kurz, M. Navratil, E. A. Arriaga, and U. T. Brunk, "Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging," Antioxidants and Redox Signaling, vol. 12, no. 4, pp. 503–535, 2010.
[19] N. G. Lambert, H. ElShelmani, M. K. Singh et al., "Risk factors and biomarkers of age-related macular degeneration," Progress in Retinal and Eye Research, vol. 54, pp. 64–102, 2016.
[20] S. Khandhadia and A. Lotery, "Oxidation and age-related macular degeneration: insights from molecular biology," Expert Reviews in Molecular Medicine, vol. 12, article e34, 2010.
[21] J. R. Sparrow, D. Hicks, and C. P. Hamel, "The retinal pigment epithelium in health and disease," Current Molecular Medicine, vol. 10, no. 9, pp. 802–823, 2010.
[22] K. Kaarniranta, J. Hyytinenn, T. Ryhanen et al., "Mechanisms of protein aggregation in the retinal pigment epithelial cells," Frontiers in Bioscience, vol. 2, no. 4, pp. 1374–1384, 2010.
[23] S. M. Reppert and D. R. Weaver, "Coordination of circadian timing in mammals," Nature, vol. 418, no. 6901, pp. 935–941, 2002.
[24] G. Tosiini and M. Menaker, "Circaadian rhythms in cultured mammalian retina," Science, vol. 272, no. 5260, pp. 419–421, 1996.
[25] J. P. DeBruyne, E. Noton, C. M. Lambert, E. S. Maywood, D. R. Weaver, and S. M. Reppert, "A clock shock: mouse CLOCK is not required for circadian oscillator function," Neuron, vol. 50, no. 3, pp. 465–477, 2006.
[26] N. Hayasaka, S. I. LaRue, and C. B. Green, "In vivo disruption of Xenopus CLOCK in the retinal photoreceptor cells abolishes circadian melatonin rhythmicity without affecting its production levels," The Journal of Neuroscience, vol. 22, no. 5, pp. 1600–1607, 2002.
[27] T. N. Ivanova and P. M. Ivunve, "Circaadian rhythm and photic control of cAMP level in chick retinal cell cultures: a mechanism for coupling the circadian oscillator to the melatonin-synthesizing enzyme, arylalkylamine N-acetyltransferase, in photoreceptor cells," Brain Research, vol. 991, no. 1-2, pp. 96–103, 2003.
[28] T. N. Ivanova and P. M. Ivunve, "Melatonin synthesis in retina: circadian regulation of arylalkylamine N-acetyltransferase activity in cultured photoreceptor cells of embryonic chicken retina," Brain Research, vol. 973, no. 1, pp. 56–63, 2003.
[29] E. Muñoz and R. Baler, "The circadian E-box: when perfect is not good enough," Chronobiology International, vol. 20, no. 3, pp. 371–388, 2003.
[31] A. Sehgal, “Ac-ing the clock,” Neuron, vol. 57, no. 1, pp. 8–10, 2008.
[32] L. Xu, G. Ruan, H. Dai, A. C. Liu, J. Penn, and D. G. McMahon, “Mammalian retinal Müller cells have circadian clock function,” Molecular Vision, vol. 22, pp. 275–283, 2016.
[33] G.-X. Ruan, D.-Q. Zhang, T. Zhou, S. Yamazaki, and D. G. McMahon, “Circadian organization of the mammalian retina,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 25, pp. 9703–9708, 2006.
[34] D. T. Organisciak, R. M. Darrow, L. Barsalou, R. K. Kutty, and B. Wiggert, “Circadian-dependent retinal light damage in rats,” Investigative Ophthalmology & Visual Science, vol. 41, no. 12, pp. 3694–3701, 2000.
[35] T. Sugawara, P. A. Sieving, P. M. Iuvone, and R. A. Bush, “The melatonin antagonist luzindole protects retinal photoreceptors from light damage in the rat,” Investigative Ophthalmology & Visual Science, vol. 39, no. 12, pp. 2458–2465, 1998.
[36] D.-X. Tan, L. C. Manchester, R. Hardeland et al., “Melatonin: a hormone, a tissue factor, an autacoid, a paracoid, and an antioxidant vitamin,” Journal of Pineal Research, vol. 34, no. 1, pp. 75–78, 2003.
[37] K. Sakamoto, C. Liu, and G. Tosini, “Circadian rhythms in the retina of rats with photoreceptor degeneration,” Journal of Neurochemistry, vol. 90, no. 4, pp. 1019–1024, 2004.
[38] P. M. Iuvone, J. H. Boatright, G. Tosini, and K. Ye, “N-Acetylsersotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain,” Advances in Experimental Medicine and Biology, vol. 801, pp. 765–771, 2014.
[39] G. Tosini, N. Pozdeyev, K. Sakamoto, and P. M. Iuvone, “The circadian clock system in the mammalian retina,” BioEssays, vol. 30, no. 7, pp. 624–633, 2008.
[40] G. Tosini, A. J. Davidson, C. Fukuhara, M. Kasamatsu, and O. Castanon-Cervantes, “Localization of a circadian clock in mammalian photoreceptors,” The FASEB Journal, vol. 21, no. 14, pp. 3866–3871, 2007.
[41] A. F. Wiechmann and J. A. Summers, “Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues,” Progress in Retinal and Eye Research, vol. 27, no. 2, pp. 137–160, 2008.
[42] S. S. Chaurasia, R. Haque, N. Pozdeyev, C. R. Jackson, and P. M. Iuvone, “Temporal coupling of cyclic AMP and Ca2+/calmodulin-stimulated adenylyl cyclase to the circadian clock in chick retinal photoreceptor cells,” Journal of Neurochemistry, vol. 99, no. 4, pp. 1142–1150, 2006.
[43] S. S. Chaurasia, N. Pozdeyev, R. Haque, A. Visser, T. N. Ivanova, and P. M. Iuvone, “Circadian clockwork machinery in neural retina: evidence for the presence of functional clock components in photoreceptor-enriched chick retinal cell cultures,” Molecular Vision, vol. 12, pp. 215–223, 2006.
[44] W. Chen and R. Baler, “The rat arylalkylamine N-acetyltransferase E-box: differential use in a master vs. a slave oscillator,” Molecular Brain Research, vol. 81, no. 1-2, pp. 43–50, 2000.
[45] R. Haque, F. G. Ali, R. Biscoglia et al., “CLOCK and NPA52 have overlapping roles in the circadian oscillation of arylalkylamine N-acetyltransferase mRNA in chicken cone photoreceptors,” Journal of Neurochemistry, vol. 113, no. 5, pp. 1296–1306, 2010.
[46] R. Haque, N. W. Chong, F. Ali et al., “Melatonin synthesis in retina: CAMP-dependent transcriptional regulation of chicken arylalkylamine N-acetyltransferase by a CRE-like sequence and a TTAAT repeat motif in the proximal promoter,” Journal of Neurochemistry, vol. 119, no. 1, pp. 6–17, 2011.
[47] T. N. Ivanova, A. L. Alonso-Gomez, and P. M. Iuvone, “Dopamine D4 receptors regulate intracellular calcium concentration in cultured chicken cone photoreceptor cells: relationship to dopamine receptor-mediated inhibition of cAMP formation,” Brain Research, vol. 1207, pp. 111–119, 2008.
[48] N. Pozdeyev, C. Taylor, R. Haque et al., “Photic regulation of arylalkylamine N-acetyltransferase binding to 14–3–3 proteins in retinal photoreceptor cells,” The Journal of Neuroscience, vol. 26, no. 36, pp. 9153–9161, 2006.
[49] P. M. Iuvone, N. W. Chong, M. Bernard, A. D. Brown, K. B. Thomas, and D. C. Klein, “Melatonin biosynthesis in chicken retina. Regulation of tryptophan hydroxylase and arylalkylamine N-acetyltransferase,” Advances in Experimental Medicine and Biology, vol. 460, pp. 31–41, 1999.
[50] J. Liang, J. H. Wessel III, P. M. Iuvone, G. Tosini, and C. Fukuhara, “Diurnal rhythms of tryptophan hydroxylase 1 and 2 mRNA expression in the rat retina,” Neuron, vol. 15, no. 9, pp. 1497–1500, 2004.
[51] G. Tosini, K. Baba, C. K. Hwang, and P. M. Iuvone, “Melatonin: an underappreciated player in retinal physiology and pathophysiology,” Experimental Eye Research, vol. 103, pp. 82–89, 2012.
[52] M. A. Zmijewski, T. W. Sweatman, and A. T. Slominski, “The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19),” Molecular and Cellular Endocrinology, vol. 307, no. 1-2, pp. 211–216, 2009.
[53] S. L. Coon, E. Del Olmo, W. Scott Young III, and D. C. Klein, “Melatonin synthesis enzymes in Macaca mulatta: focus on arylalkylamine N-acetyltransferase (EC 2.3.1.87),” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4699–4706, 2002.
[54] E. Savaskan, R. Jockers, M. Ayoub et al., “The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer’s disease,” Current Alzheimer Research, vol. 4, no. 1, pp. 47–51, 2007.
[55] A. F. Wiechmann and M. A. Burden, “Regulation of AA-NAT and HIOMT gene expression by butyrate and cyclic AMP in Y79 human retinoblastoma cells,” Journal of Pineal Research, vol. 27, no. 2, pp. 116–121, 1999.
[56] J. L. Peters and V. M. Cassone, “Melatonin regulates circadian electroretinogram rhythms in a dose- and time-dependent fashion,” Journal of Pineal Research, vol. 38, no. 3, pp. 209–215, 2005.
[57] M. Rufanje, M. Dumont, and P. Lachapelle, “Correlating retinal function with melatonin secretion in subjects with an early or late circadian phase,” Investigative Ophthalmology & Visual Science, vol. 43, no. 7, pp. 2491–2499, 2002.
[58] M. Rufanje, S. Rousseau, O. Dembinska, and P. Lachapelle, “Cone-dominated ERG luminance-response function: the Photopic Hill revisited,” Documenta Ophthalmologica, vol. 104, no. 3, pp. 231–248, 2002.
[59] S. Hiragaki, K. Baba, E. Coulson, S. Kunst, R. Spessert, and G. Tosini, “Melatonin signaling modulates clock genes expression in the mouse retina,” PLoS ONE, vol. 9, no. 9, Article ID e106819, 2014.
[60] A. Sengupta, K. Baba, F. Mazzoni et al., “Localization of melatonin receptor 1 in mouse retina and its role in the circadian regulation of the electroretinogram and dopamine levels,” PLoS ONE, vol. 6, no. 9, Article ID e24483, 2011.
A. Kijlstra and T. T. J. M. Berendschot, "Age-related macular degeneration: new clues into the pathogenesis," *American Journal of Ophthalmology*, vol. 161, pp. 78–93.e2, 2016.

M. L. Katz, "Potential role of retinal pigment epithelial lipofuscin accumulation in age-related macular degeneration," *Archives of Gerontology and Geriatrics*, vol. 34, no. 3, pp. 359–370, 2002.

L. G. Fritsche, R. N. Fariss, D. Stambolian, G. R. Abecasis, C. A. Curcio, and A. Swaroop, "Age-related macular degeneration: genetics and biology coming together," *Annual Review of Genomics and Human Genetics*, vol. 15, pp. 151–171, 2014.

A. Kijlstra and T. T. J. M. Berendschot, "Age-related macular degeneration: a complementopathy?" *Ophthalmic Research*, vol. 54, no. 2, pp. 64–73, 2015.

M. L. Lambros and S. M. Plafker, "Oxidative stress and the Nrf2 anti-oxidant transcription factor in age-related macular degeneration," *Advances in Experimental Medicine and Biology*, vol. 854, pp. 67–72, 2016.

L. M. Pujol-Lereis, N. Schäfer, L. B. Kuhn, B. Rohrer, and D. J.-Y. Kim, H. Zhao, J. Martinez et al., "Noncanonical autophagy activation in models of age-related macular degeneration," *Advances in Experimental Medicine and Biology*, vol. 854, pp. 87–93, 2016.

J. Blasiak, J. Szaflik, and J. P. Szaflik, "Implications of altered iron homeostasis for age-related macular degeneration," *Frontiers in Bioscience*, vol. 16, no. 4, pp. 1551–1559, 2011.

E. Kaemmerer, F. Schutt, T. U. Krohne, F. G. Holz, and J. Koptiz, "Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis," *Investigative Ophthalmology and Visual Science*, vol. 48, no. 3, pp. 1342–1347, 2007.

J.-Y. Kim, H. Zhao, J. Martinez et al., "Noncanonical autophagy promotes the visual cycle," *Cell*, vol. 154, no. 2, pp. 365–376, 2013.

M. Suzuki, M. Kamei, H. Itabe et al., "Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration," *Molecular Vision*, vol. 13, pp. 772–778, 2007.

M. D. Pinazo-Durán, F. Gómez-Ulla, L. Arias et al., "Do nutritional supplements have a role in age macular degeneration prevention?" *Journal of Ophthalmology*, vol. 2014, Article ID 901686, 15 pages, 2014.

A. Koskela, M. Reimisalo, G. Petrovski et al., "Nutriceutical with resveratrol and omega-3 fatty acids induces autophagy in ARPE-19 cells," *Nutrients*, vol. 8, no. 5, p. 284, 2016.

R. Olimski, M. Starczak, and D. Gackowski, "Enigmatic 5-hydroxytryptamincide: oxidatively modified base, epigenetic mark or both?" *Mutation Research. Reviews in Mutation Research*, vol. 767, pp. 59–66, 2016.

M. Akbari, M. Morevati, D. Croteau, and V. A. Bohr, "The role of DNA base excision repair in brain homeostasis and disease," *DNA Repair*, vol. 32, pp. 172–179, 2015.

B. Poljsak, D. Supt and, I. Milisav, "Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants," *Oxidative Medicine and Cellular Longevity*, vol. 2013, Article ID 956792, 11 pages, 2013.

J. Blasiak, E. Synowiec, A. Salminen, and K. Kaarniranta, "Genetic variability in DNA repair proteins in age-related macular degeneration," *International Journal of Molecular Sciences*, vol. 13, no. 10, pp. 13378–13397, 2012.

P. X. Shaw, L. Zhang, M. Zhang et al., "Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 34, pp. 13757–13762, 2012.

A. Kauppinen, J. J. Paterno, J. Blasiak, A. Salminen, and K. Kaarniranta, "Inflammation and its role in age-related macular degeneration," *Cellular and Molecular Life Sciences*, vol. 73, no. 9, pp. 1765–1786, 2016.

M. L. Fanjul-Moles and G. O. López-Riquelme, "Relationship between oxidative stress, circadian rhythms, and AMD," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 7420637, 18 pages, 2016.

M. R. Ramis, S. Esteban, A. Miralles, D.-X. Tan, and R. J. Reiter, "Protective effects of melatonin and mitochondria-targeted antioxidants against oxidative stress: a review," *Current Medicinal Chemistry*, vol. 22, no. 22, pp. 2690–2711, 2015.

T. W. Fischer, A. Slominski, M. A. Zmijewski, J. R. Reiter, and R. Paus, "Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair," *Experimental Dermatology*, vol. 17, no. 9, pp. 713–730, 2008.

A. W. Siu, M. Maldonado, M. Sanchez-Hidalgo, D.-X. Tan, and R. J. Reiter, "Protective effects of melatonin in experimental free radical-related ocular diseases," *Journal of Pineal Research*, vol. 40, no. 2, pp. 101–109, 2006.

P. L. Marchiafava and B. Longoni, "Melatonin as an antioxidant in retinal photoreceptors," *Journal of Pineal Research*, vol. 26, no. 3, pp. 184–189, 1999.

A. W. Siu, R. J. Reiter, and C. H. To, "Pinel indoleamines and vitamin E reduce nitric oxide-induced lipid peroxidation in rat retinal homogenates," *Journal of Pineal Research*, vol. 27, no. 2, pp. 122–128, 1999.

M. H. Guajardo, A. M. Terrasa, and A. Catalá, "Protective effect of indoleamines on in vitro ascorbate-Fe2+ dependent lipid peroxidation of rod outer segment membranes of bovine retina," *Journal of Pineal Research*, vol. 35, no. 4, pp. 276–282, 2003.

R. B. Rosen, D.-N. Hu, M. Chen, S. A. McCormick, J. Walsh, and J. E. Roberts, "Effects of melatonin and its receptor antagonist on retinal pigment epithelial cells against hydrogen peroxide damage," *Molecular Vision*, vol. 18, pp. 1640–1648, 2012.

N. Cantu-Medellin and E. E. Kelley, "Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how," *Nitric Oxide*, vol. 34, pp. 19–26, 2013.

N. E. Fox and F. J. G. M. van Kuijk, "Immunohistochemical localization of xanthine oxidase in human retina," *Free Radical Biology and Medicine*, vol. 24, no. 6, pp. 900–905, 1998.

M.-C. Lee, Y.-T. Chung, J.-H. Lee, J.-J. Jung, H.-S. Kim, and S. U. Kim, "Antioxidant effect of melatonin in human retinal neuron cultures," *Experimental Neurology*, vol. 172, no. 2, pp. 407–415, 2001.

A. W. Siu, R. J. Reiter, and C. H. To, "The efficacy of vitamin E and melatonin as antioxidants against lipid peroxidation in rat retinal homogenates," *Journal of Pineal Research*, vol. 24, no. 4, pp. 239–244, 1998.

F.-Q. Liang, L. Green, C. Wang, R. Alssadi, and B. F. Godley, "Melatonin protects human retinal pigment epithelial (RPE) cells against oxidative stress," *Experimental Eye Research*, vol. 78, no. 6, pp. 1069–1075, 2004.

T. Yilmaz, S. Celebi, and A. S. Kukner, "The protective effects of melatonin, vitamin E and octreotide on retinal edema."
during ischemia-reperfusion in the guinea pig retina,” *European Journal of Ophthalmology*, vol. 12, no. 6, pp. 443–449, 2002.

[93] A. Greco, M. I. Rizzo, A. De Virgilio, A. Gallo, M. Fusconi, and M. de Vincentis, “Emerging concepts in glaucoma and review of the literature,” *The American Journal of Medicine*, vol. 129, no. 9, pp. 1000.e7–1000.e13, 2016.

[94] M. Nita and A. Grzybowski, “The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3164734, 23 pages, 2016.

[95] M. C. Moreno, J. Campanelli, P. Sande, D. A. Sáenz, M. I. Keller Sarmiento, and R. E. Rosenstein, “Retinal oxidative stress induced by high intraocular pressure,” *Free Radical Biology and Medicine*, vol. 37, no. 6, pp. 803–812, 2004.

[96] A. Martinez-Águla, B. Fonseca, M. J. Pérez de Lara, and J. Pintor, “Effect of melatonin and 5-methoxy carbonyl amino-N-acetyltryptamine on the intraocular pressure of normal and glaucomatous mice,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 357, no. 2, pp. 293–299, 2016.

[97] T.-T. Wan, X.-F. Li, Y.-M. Sun, Y.-B. Li, and Y. Su, “Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy,” *Biomedicine and Pharmacotherapy*, vol. 74, pp. 145–147, 2015.

[98] T. Jiang, Q. Chang, J. Cai, J. Fan, X. Zhang, and G. Xu, “Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3528274, 13 pages, 2016.

[99] G. A. Bubenik and S. J. Konturek, “Melatonin and aging: prospects for human treatment,” *Journal of Physiology and Pharmacology*, vol. 62, no. 1, pp. 13–19, 2011.

[100] K. Baba, F. Mazzoni, S. Owino, S. Contreras-Alcantara, E. Strettoi, and G. Tosini, “Age-related changes in the daily rhythm of photoreceptor functioning and circuitry in a melanin-proficient mouse strain,” *PLoS ONE*, vol. 7, no. 5, Article ID e37799, 2012.

[101] C. Yi, X. Pan, H. Yan, M. Guo, and W. Pierpaoli, “Protective effects of melatonin in experimental animal models,” *Molecular Vision*, vol. 10, pp. 384–392, 2005.

[102] O. Pulido and J. Clifford, “Age-associated changes in the circadian rhythm of retinal n-acetylserotonin and melatonin in rats with pigmented eyes,” *Experimental Gerontology*, vol. 21, no. 1, pp. 23–30, 1986.

[103] G. Tosini, S. S. Chaurasia, and P. M. Iuvone, “Regulation of arylalkylamine N-acetyltransferase (AANAT) in the retina,” *Chronobiology International*, vol. 23, no. 1-2, pp. 381–391, 2006.

[104] R. Rosen, D.-N. Hu, V. Perez et al., “Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients,” *Molecular Vision*, vol. 15, pp. 1673–1679, 2009.

[105] C. Köhle and K. W. Bock, “Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and NrF2,” *Biochemical Pharmacology*, vol. 73, no. 12, pp. 1853–1862, 2007.

[106] Q. Ma and X. He, “Molecular basis of electrophilic and oxidative defense: promises and perils ofNrF2,” *Pharmacological Reviews*, vol. 64, no. 4, pp. 1055–1081, 2012.

[107] M. L. Perepechaeva, N. A. Stefanova, and A. Y. Grishanova, “Expression of genes for AhR and NrF2 signal pathways in the retina of OXYs rats during the development of retinopathy and melanin-induced changes in this process,” *Bulletin of Experimental Biology and Medicine*, vol. 157, no. 4, pp. 424–429, 2014.

[108] H. Matsunaga, J. T. Handa, A. Aotaki-Keen, S. W. Sherwood, M. D. West, and L. M. Hjelmeland, “Beta-galactosidase histochemistry and telomere loss in senescent retinal pigment epithelial cells,” *Investigative Ophthalmology & Visual Science*, vol. 40, no. 1, pp. 197–202, 1999.

[109] T. von Zglinicki, G. Saretzki, W. Döcke, and C. Lotze, “Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence?” *Experimental Cell Research*, vol. 220, no. 1, pp. 186–193, 1995.

[110] R. Rastmanesh, “Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity,” *Medical Hypotheses*, vol. 76, no. 1, pp. 79–85, 2011.

[111] B. W. M. Lau, G. S. W. Tsao, K. F. So, and H. K. Yip, “Expression of telomerase reverse transcriptase in adult goldfish retina,” *Journal of Molecular Neuroscience*, vol. 32, no. 2, pp. 160–167, 2007.

[112] X. Min, Q. Zhou, X. Dong, Y. Wang, and L. Xie, “Expression profile and regulation of telomerase reverse transcriptase on oxygen-induced retinal neovascularization,” *Current Eye Research*, vol. 36, no. 2, pp. 135–142, 2011.

[113] M. Akiyama, K. Ozaki, T. Kawano et al., “Telomerase activation as a repair response to radiation-induced DNA damage in Y79 retinoblastoma cells,” *Cancer Letters*, vol. 340, no. 1, pp. 82–87, 2013.

[114] G. Yang, D. G. Rosen, J. A. Colacino, I. Mercado-Uribe, and J. Liu, “Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells,” *Oncogene*, vol. 26, no. 10, pp. 1492–1498, 2007.

[115] C. Kaur, W. S. Foulds, and E. A. Ling, “Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management,” *Progress in Retinal and Eye Research*, vol. 27, no. 6, pp. 622–647, 2008.

[116] C. Kaur, W. S. Foulds, and E. A. Ling, “Hypoxia-ischemia and retinal ganglion cell damage,” *Journal of Clinical Ophthalmology*, vol. 2, no. 4, pp. 879–889, 2008.

[117] V. Sivakumar, J. Lu, E. A. Ling, and C. Kaur, “Vascular endothelial growth factor and nitric oxide production in response to hypoxia in the choroid plexus in neonatal brain,” *Brain Pathology*, vol. 18, no. 1, pp. 71–85, 2008.

[118] M. Amadio, S. Govoni, and A. Pascale, “Targeting VEGF in eye neovascularization: what's new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development,” *Pharmacological Research*, vol. 103, pp. 253–269, 2016.

[119] M. K. Tsilimbaris, M. I. Lopez-Galvez, R. Gallego-Pinazo, P. Margaron, and G. N. Lambrou, “Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD,” *Journal of Ophthalmology*, vol. 2016, Article ID 4367631, 13 pages, 2016.

[120] G. C. Brainard, J. R. Hanifin, J. M. Greeson et al., “Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor,” *The Journal of Neuroscience*, vol. 21, no. 16, pp. 6405–6412, 2001.

[121] T. Nishi, K. Saeki, K. Obayashi et al., “The effect of blue-blocking intraocular lenses on circadian biological rhythm: protocol for a randomised controlled trial (CLOCK-IOL colour study),” *BMJ Open*, vol. 5, no. 5, Article ID e007930, 2015.

[122] M. A. Mainster and P. L. Turner, “Blue-blocking IOLs decrease photoreception without providing significant photoprotection,” *Survey of Ophthalmology*, vol. 55, no. 3, pp. 272–283, 2010.
[123] D. A. Ferrington, R. J. Kapphahn, M. M. Leary et al., “Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration,” *Experimental Eye Research*, vol. 145, pp. 269–277, 2016.

[124] L. S. Frost, C. H. Mitchell, and K. Boesze-Battaglia, “Autophagy in the eye: implications for ocular cell health,” *Experimental Eye Research*, vol. 124, pp. 56–66, 2014.

[125] A. Coto-Montes, J. A. Boga, S. Rosales-Corral, L. Fuentes-Broto, D.-X. Tan, and R. J. Reiter, “Role of melatonin in the regulation of autophagy and mitophagy: a review,” *Molecular and Cellular Endocrinology*, vol. 361, no. 1-2, pp. 12–23, 2012.

[126] A. Fernández, R. Ordóñez, R. J. Reiter, J. González-Gallego, and J. L. Mauriz, “Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis,” *Journal of Pineal Research*, vol. 59, no. 3, pp. 292–307, 2015.

[127] M. Karbowski and R. J. Youle, “Dynamics of mitochondrial morphology in healthy cells and during apoptosis,” *Cell Death and Differentiation*, vol. 10, no. 8, pp. 870–880, 2003.

[128] S. M. Plafker, G. B. O’Mealey, and L. I. Szweda, “Mechanisms for countering oxidative stress and damage in retinal pigment epithelium,” *International Review of Cell and Molecular Biology*, vol. 298, pp. 135–177, 2012.

[129] J. Blasiak, S. Glowacki, A. Kauppinen, and K. Kaarniranta, “Mitochondrial and nuclear DNA damage and repair in age-related macular degeneration,” *International Journal of Molecular Sciences*, vol. 14, no. 2, pp. 2996–3010, 2013.

[130] K. M. Litts, J. D. Messinger, K. B. Freund, Y. Zhang, and C. A. Curcio, “Inner segment remodeling and mitochondrial translocation in cone photoreceptors in age-related macular degeneration with outer retinal tubulation,” *Investigative Ophthalmology & Visual Science*, vol. 56, no. 4, pp. 2243–2253, 2015.

[131] J. W. Shay, “Role of telomeres and telomerase in aging and cancer,” *Cancer Discovery*, vol. 6, article 584, 2016.

[132] C. Rowe-Rendleman and R. D. Glickman, “Possible therapy for age-related macular degeneration using human telomerase,” *Aging Research Reviews*, vol. 15, no. 11, pp. 5470–5479, 2010.

[133] L. C. Manchester, A. Coto-Montes, J. A. Boga et al., “Melatonin: an ancient molecule that makes oxygen metabolically tolerable,” *Journal of Pineal Research*, vol. 59, no. 4, pp. 403–419, 2015.

[134] J. Kovács, W. Brodner, V. Kirchlechner, T. Arif, and F. Waldhauser, “Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 85, no. 2, pp. 666–670, 2000.